1. Report Overview
1.1 Overview of the Nanomedicine Industry and Market
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Nanomedicine
2.1 Nanotechnology – Definition
2.2 Nanomedicine – Size Should Not be the Main Definition
2.3 Nanotechnology – Solutions and Improvements in Medicine
2.4 Nanomedicine – Types of Applications
2.4.1 Drug Delivery
2.4.2 Nanodrugs
2.4.2.1 Nanoparticles – Combinations of Three Dimensions
2.4.2.1.1 Liposomes
2.4.2.1.2 Polymers
2.4.2.1.3 Quantum Dots
2.4.2.1.4 Superparamagnetic Iron Oxide (SPIO)
2.4.2.1.5 Carbon Nanotubes
2.4.2.1.6 Carbon Nanoshells
2.4.2.2 Nanoparticle Functionalisation
2.4.2.2.1 Targeting
2.4.2.2.2 Surface Conjugation
2.4.2.2.3 Improved Bioavailability
2.4.2.2.4 Tunability
2.4.2.2.5 Controlled Release
2.4.3 Implants
2.4.4 Diagnostics
2.4.4.1 Diagnostic Tools
2.4.4.2 Medical Instruments
2.4.4.3 Imaging Tools
2.4.4.4 Theranostics
3. Global Nanomedicine Market, 2015-2025
3.1 Revenue Forecasts of Nanomedicine by Therapeutic Area
3.1.1 Forecast of Nanomedicine for Oncology 2015-2025
3.1.2 Forecast of Nanomedicine for Cardiovascular Uses 2015-2025
3.1.3 Forecast of Nanomedicine for Anti-inflammatory Uses 2015-2025
3.1.4 Forecast of Nanomedicine for Neurology 2015-2025
3.1.5 Forecast of Nanomedicine for Anti-Infective 2015-2025
3.1.6 Forecast of Nanomedicine for Other Therapeutic Areas 2015-2025
4. Nanomedicine Products – Commercial Outlooks from 2015
4.1 Nanomedicine Products – Segmentation
4.1.1 Nanomedicine Products in the Market – Revenue Potentials, 2015-2025
4.1.1.1 Abraxane (Celgene)
4.1.1.2 Doxil (Janssen)
4.1.1.3 Myocet (Teva Pharmaceuticals)
4.1.1.4 ONCASPAR (Baxalta)
4.1.1.5 Alimta (Eli Lilly)
4.1.1.6 Eligard (Sanofi)
4.1.1.7 DaunoXome (Galen)
4.1.1.8 Copaxone (Teva)
4.1.1.9 Rapamune (PF Prism)
4.1.1.10 Neulasta (Amgen)
4.1.1.11 Cimzia (UCB)
4.1.1.12 AmBisome (Astellas Pharma)
4.1.1.13 MIRCERA (Roche)
4.1.1.14 Pegasys (Roche)
4.1.1.15 Emend (Merck)
4.1.1.16 Renagel (Genzyme)
4.1.1.17 Ritalin (Novartis)
5. Leading National Markets, 2015-2025
5.1 Nanomedicine – Leading Markets, 2014
5.2 The US Nanomedicine Market, 2015-2025
5.3 The Japanese Nanomedicine Market, 2015-2025
5.4 The EU Nanomedicine Market, 2015-2025
5.5 The Asia-Pacific Nanomedicine Market, 2015-2025
5.6 Rest of the World Nanomedicine Market, 2015-2025
6. Profiles of Pharmaceutical Companies with Nanotechnology Related Applications
6.1 Sanofi
6.2 BIND Therapeutics
6.3 Merck
6.4 Pfizer
6.5 Cerulean Pharma
6.6 Selecta Biosciences
6.7 Nanobiotix
6.8 Magforce
6.9 Celgene
6.10 Celsion Corporation
6.11 Nanocarrier
7. Research & Development
7.1 Nanoparticles and Nano-enabled Drugs in the Pipeline
7.1.1 DermaVir (Genetic Immunity)
7.1.2 CRLX101 (Cerulean Pharma)
7.1.3 CPX-351 (Celator Pharma)
7.1.4 NC-6004 (NanoCarrier Co.)
7.1.5 NK-105 (Nippon Kayaku Co. Ltd.)
7.1.6 NK-012 (Nippon Kayaku Co. Ltd.)
7.1.7 SGT-53 (SynerGene Therapeutics)
7.1.8 BIND-014 (BIND Biosciences)
7.1.9 ThermoDox (Celsion)
7.1.10 ADI-PEG 20 (Polaris)
8. Qualitative Analysis of the Nanomedicine Market, 2015
8.1 Room for Improvement
8.1.1 Safety and Toxicology Often Yet to be Determined
8.1.2 Establishment of Structures and Collaborations
8.1.3 Regulatory – The Need for Clear Guidelines and Harmonization
9. Research Interviews, 2015
9.1 Dr Peter Wick, Empa, the Swiss Federal Laboratories for Materials Science and Technology
9.1.1 Connecting the Key Players in the Nanomedical Sector in Europe
9.1.2 Nanomedicine Industry in Europe – In Need of an Infrastructure
9.1.3 EU-NCL: Bridging the Major Gaps and Challenges
9.2 Dr Peter D. Suzdak, CEO, Rexahn Pharmaceuticals
9.2.1 Precision-Targeted Therapy – Revolutionizes Cancer Treatment
9.2.2 RX-21101 – Included in NCL’s Preclinical Characterization Program
9.2.3 Rexahn’s NPDCS Technology – Next Generation Approach to Chemotherapy
9.2.4 Rexahn’s Polymer-Drug Conjugate – Improves Efficacy and Reduces Side Effects
9.3 Dr Joost Holthuis, CEO, Cristal Therapeutics, Netherlands
9.3.1 Nanomedicine Industry in Europe
9.3.2 CriPec Based Nanomedicines – Overcome the Drawbacks of Conventional Therapies
9.3.3 CriPec Platform – All the Best Features in a Single System
9.3.4 CriPec Docetaxel – Lead Candidate Product
9.3.5 In Development – CriPec Actively Targeted Nanoparticles Platform
9.3.6 Competitive Advantage Can be Achieved Through Partnering of Parties
10. Conclusions of the Research and Analysis
10.1 Nanotechnology Holds Great Promise in Healthcare
10.2 More Research Needed to Establish Safety
10.3 Harmonization in Definition and Guidelines
Table 2.1 Advantages of Nanotechnology in Medicine
Table 2.2 Challenges and Solutions - NDDS
Table 3.1 The Global Nanomedicine Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.2 Global Nanomedicine Anti-Cancer Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.3 Global Nanomedicine CVD Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.4 Global Nanomedicine Anti-Inflammatory Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.5 Global Nanomedicine CNS Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.6 Global Nanomedicine Anti-Infectives Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.7 Global Nanomedicine Other Therapeutic Areas Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.1 Abraxane Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.2 Alimta Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.3 Eligard Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.4 Copaxone Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.5 Rapamune Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.6 Neulasta Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.7 Cimzia Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.8 AmBisome Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.9 MIRCERA Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.10 Pegasys Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.11 Emend Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.12 Renagel Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.13 Ritalin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.1 Nanomedicine Market Revenues ($bn) for Leading Regions, 2014-2025
Table 5.2 Nanomedicine Market Share(%) by Leading Regions, 2014-2025
Table 5.3 Prominent Nanomedicine Companies in the US, 2014
Table 5.4 The US Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.5 The Japanese Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.6 EU Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.7 Prominent Nanomedicine Companies in the UK, 2014
Table 5.8 Prominent Nanomedicine Companies in Germany, 2014
Table 5.9 Prominent Nanomedicine Companies in France, 2014
Table 5.10 Asia Pacific Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.11 RoW Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 8.1 Strengths, Weaknesses, Opportunities and Threats in the Nanomedicine Market, 2015
Figure 1.1 Nanomedicine - Segmented by Application
Figure 2.1 Applications of Nanotechnology in Diagnostics
Figure 2.2 Applications of Nanotechnology in Therapeutics
Figure 2.3 Systems Used in Nanotechnology-enabled Drug Delivery
Figure 2.4 Market Shares of NDDS by System, 2014
Figure 2.5 NDDS: Market Drivers and Restraints, 2015-2025
Figure 2.6 Representation of Nanoparticles
Figure 2.7 Combinations of Layers that Form Nanoparticles
Figure 2.8 Nanoparticles: Market Drivers and Restraints 2015-2025
Figure 2.9 Implants: Market Drivers and Restraints, 2015-2025
Figure 2.10 Diagnostics: Market Drivers and Restraints, 2015-2025
Figure 2.11 Theranostics: Market Drivers and Restraints, 2015-2025
Figure 3.1 Global Nanomedicine Anti-Cancer Market: Revenue Forecast ($bn), 2015-2025
Figure 3.2 Applications of Nanotechnology in the Cardiovascular Therapeutic Area
Figure 3.3 Global Nanomedicine CVD Market: Revenue Forecast ($bn), 2015-2025
Figure 3.4 Global Nanomedicine Anti-Inflammatory Market: Revenue Forecast ($bn), 2015-2025
Figure 3.5 Global Nanomedicine CNS Market: Revenue Forecast ($bn), 2015-2025
Figure 3.6 Global Nanomedicine Anti-Infectives Market: Revenue Forecast ($bn), 2015-2025
Figure 3.7 Global Nanomedicine Other Therapeutic Areas Market: Revenue Forecast ($bn), 2015-2025
Figure 4.1 Nanomedicine - Segmented by Application
Figure 4.2 Proportions of Nano Products by Application, 2014
Figure 4.3 Proportions of Nano Products by Therapeutic Area, 2014
Figure 4.4 Abraxane Revenue Forecast ($bn), 2015-2025
Figure 4.5 Alimta Revenue Forecast ($bn), 2015-2025
Figure 4.6 Eligard Revenue Forecast ($bn), 2015-2025
Figure 4.7 Copaxone Revenue Forecast ($bn), 2015-2025
Figure 4.8 Rapamune Revenue Forecast ($bn), 2015-2025
Figure 4.9 Neulasta Revenue Forecast ($bn), 2015-2025
Figure 4.10 Cimzia Revenue Forecast ($bn), 2015-2025
Figure 4.11 AmBisome Revenue Forecast ($bn), 2015-2025
Figure 4.12 MIRCERA Revenue Forecast ($bn), 2015-2025
Figure 4.13 Pegasys Revenue Forecast ($bn), 2015-2025
Figure 4.14 Emend Revenue Forecast ($bn), 2015-2025
Figure 4.15 Renagel Revenue Forecast ($bn), 2015-2025
Figure 4.16 Ritalin Revenue Forecast ($bn), 2015-2025
Figure 5.1 Leading National Nanomedicine Markets by Share of Global Market (%), 2014
Figure 5.2 Leading National Nanomedicine Markets by Share of Global Market (%), 2019
Figure 5.3 Leading National Nanomedicine Markets by Share of Global Market (%), 2025
Figure 5.4 The US Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
Figure 5.5 The Japanese Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
Figure 5.6 EU Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
Figure 5.7 Asia Pacific Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
Figure 5.8 RoW Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
Figure 7.1 Proportion of Products by Therapeutic Area in Clinical Trials, 2014
Figure 7.2 Products in Clinical Trials by Developmental Phase, 2014
【レポートのキーワード】
ナノメディシン、治療、用途、ナノ技術、医薬品、アブラキサン、ドキシル、製薬